RxDoctor Payments Data

Karthik Mohan, DO

Gastroenterology · Hialeah, FLNPI 1447695564

Payments from drug & device makers

$2,794in general payments, 2019–2025

Across 124 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$811
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$556
  • Redhill Biopharma Inc.$220
  • Madrigal Pharmaceuticals$185
  • Takeda Pharmaceuticals U.S.A., Inc.$180
  • Ferring Pharmaceuticals Inc.$152
  • plus $689 from 14 others

What the payments were for

  • Consulting fees$110%
  • Food & beverage$2,70497%
  • Gifts$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,794 in reported general payments places this provider in the 40th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$367,049
Medicare patients
725
Services billed
3,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom26$104,320
RemicadeInfliximab15$64,656
LinzessLinaclotide71$50,689
VemlidyTenofovir Alafenamide17$27,643
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates276$17,706
SuprepSodium, Potassium,mag Sulfates86$7,109
Dexlansoprazole DrDexlansoprazole12$2,508
Esomeprazole Magnesium88$1,615
Pantoprazole Sodium207$1,335
Omeprazole107$944
Dicyclomine Hcl46$732
Lactulose26$604
Famotidine75$417
Metronidazole17$230
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$185$104,32026 claims
Johnson & JohnsonRemicade$20$64,65615 claims
AbbVieLinzess$811$50,68971 claims
GileadVemlidy$90$27,64317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →